Impact of SCFA Supplementation on Gut Microbiome Composition of Kidney Transplant Recipients

Launched by UNIVERSITY HOSPITAL, MARTIN · Jun 8, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Primary kidney transplantation (living or dead donor)
• • Stable kidney transplant recipients (≥ 6 months post-transplantation)
• • Stable graft function defined as eGFR ≥ 30 mL/min/1.73 m² with no significant change (\>15%) in the last 3 months
• • No episodes of acute rejection within the last 6 months
• • On stable immunosuppressive therapy for at least 3 months
• • Ability to provide written informed consent
• • Willingness and ability to provide stool, urine, and blood samples at specified time points
• Exclusion Criteria:
• • Use of antibiotics, probiotics, or prebiotics within 4 weeks prior to enrollment
• • Active gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, celiac disease)
• • Severe intestinal motility disorders or chronic diarrhea
• • Advanced liver disease (Child-Pugh C)
• • Active infection or systemic inflammatory disease requiring treatment
• • Uncontrolled diabetes mellitus (HbA1c \> 9%)
• • Known allergy or intolerance to SCFA or ingredients in the supplement
• • Participation in another interventional clinical trial within the past 30 days
• • Pregnancy or breastfeeding
• • Hospitalization within 30 days prior to enrollment
• • Any condition which, in the opinion of the investigator, may compromise the safety of the participant or the integrity of the study data